Novo Nordisk announced on Wednesday that it is trimming its full-year profit outlook following weaker-than-expected quarterly sales of its popular weight-loss drug,
Shares in Novo Nordisk, maker of the obesity drug Wegovy, fell 1.9% on Tuesday following the publication of a data analysis in
The Senate Committee on Health, Education, Labor, and Pensions (HELP) recently announced a significant development regarding the pricing of Novo Nordisk’s weight
Researchers have specified specific genetic markers that may predict which patients with obesity are most likely to respond strongly to Novo Nordisk’s weight-loss